Table 1.
General characteristics of study population by vaccine type and COVID-19 statusc
| mRNA vaccinea (n = 2,093,700, 62.48%) | Othersb (n = 1,257,155, 37.52%) | ||||
|---|---|---|---|---|---|
| Infected (n = 1,388, 0.07%) |
Not infected (n = 2,092,312, 99.93%) |
Infected (n = 194, 0.02%) |
Not infected (n = 1,256,961, 99.98%) |
||
| n (%) | n (%) | n (%) | n (%) | P–value | |
| Occurrence of heart disease | <.0001 | ||||
| Yes | 6 (0.43) | 2,679 (0.13) | 1 (0.52) | 1,078 (0.09) | |
| No | 1,382 (99.57) | 2,089,633 (99.87) | 193 (99.48) | 1,255,883 (99.91) | |
| Sex | <.0001 | ||||
| Male | 605 (43.59) | 796,673 (38.08) | 76 (39.18) | 529,577 (42.13) | |
| Female | 783 (56.41) | 1,295,639 (61.92) | 118 (60.82) | 727,384 (57.87) | |
| Age group | <.0001 | ||||
| 10–19 | 147 (10.59) | 126,143(6.03) | 0 (0.00) | 43 (0.00) | |
| 20–29 | 254 (18.30) | 273,981 (13.09) | 1 (0.52) | 11,341(0.90) | |
| 30–39 | 223(16.07) | 257,933 (12.33) | 24 (12.37) | 90,235 (7.18) | |
| 40–49 | 291 (20.97) | 370,719 (17.72) | 29 (14.95) | 35,161 (7.57) | |
| 50–59 | 372 (26.80) | 541,629 (25.89) | 18 (9.28) | 103,755 (8.25) | |
| 60–69 | 34 (2.45) | 58,842 (2.81) | 95 (48.97) | 683,796 (54.40) | |
| 70+ | 67 (4.83) | 463,065(22.13) | 27 (13.92) | 272,630 (21.69) | |
| Charlson comorbidity index | <.0001 | ||||
| 0 | 1,228 (88.47) | 1,728,506 (82.61) | 159 (81.96) | 972,352 (77.36) | |
| 1 | 138 (9.94) | 305,439 (14.60) | 29 (14.95) | 236,746 (18.83) | |
| 2+ | 22 (1.59) | 58,367 (2.79) | 6 (3.09) | 47,863 (3.81) | |
a
The mRNA vaccines consist of BNT162b2 and mRNA-1273.
b
Other vaccines include AZD1222 (AstraZeneca), JNJ-78436735 (Janssen), and NVX-CoV2373 (Novavax).
c
COVID-19 status was defined as yes if infected before 21 days after the first dose vaccination date.